Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: A systematic review and meta‐analysis

Abstract Polypoidal choroidal vasculopathy (PCV) is an aneurismal type of macular neovascularization that show similarities with age‐related macular degeneration and diseases that are part of the pachychoroid disease spectrum. Exudative changes in PCV can be treated with intravitreal anti‐vascular endothelial growth factor monotherapy; however, a combination therapy with photodynamic therapy may be required. In this systematic review and meta‐analysis, we evaluated the efficacy of faricimab for PCV. We searched 12 literature databases for eligible studies. All study evaluation and data extraction were made by two authors in duplicate. Studies eligible for analysis were included for a qualitative and quantitative review. We identified seven studies with data from 150 eyes with PCV, five studies were of treatment‐naïve eyes who were commenced in faricimab monotherapy, and two studies were of switch‐over to faricimab from other anti‐VEGF drugs. After faricimab loading dose in treatment‐naïve eyes, the best‐corrected visual acuity (BCVA) remained stable at −0.09 (95% CI: −0.20–0.03) logMAR, central retinal thickness (CRT) decreased −169 (95% CI: −311–−27) μm, and 48.7 (95% CI: 32.5–65.0) % of eyes obtained polyp closure. In switch‐over eyes, 57%–67% experienced fluid reduction and 21% were able to extend their treatment interval. In conclusion, faricimab monotherapy for PCV leads to acceptable clinical outcomes in terms of stable BCVA, reduction of CRT, and high incidence of polyp closure. Some cases may benefit from a switch to faricimab. However, long‐term efficacy studies and controlled comparative studies are warranted.